As new C. diff treat­ments prep for mar­ket, spe­cial­ists di­vid­ed on 'poop in a pil­l' or small mol­e­cule, study finds

What do physi­cians think about the emerg­ing mar­ket for re­cur­rent C. diff? That de­pends on who you talk to, es­pe­cial­ly which spe­cial­ists you talk to.

Fe­cal mi­cro­bio­ta trans­plants, or FMT, are fa­vored by gas­troen­terol­o­gists fa­mil­iar with them, while in­fec­tious dis­ease doc­tors pre­fer tra­di­tion­al small mol­e­cule ther­a­pies, ac­cord­ing to a re­cent fu­ture mar­ket eval­u­a­tion by Spher­ix Glob­al In­sights. While cur­rent FMT in­volves trans­plant­i­ng healthy stool in­to a C. diff pa­tient through a colonoscopy, FMT en­cap­su­lat­ed mi­cro­bio­me pills that are swal­lowed – re­ferred to by doc­tors as “poop in a pill” in Spher­ix’s in­ter­views – are like­ly on the way to mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.